+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Periodontitis - Pipeline Review, H2 2020

  • ID: 5146912
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 57 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Beijing SH Bio-Tech Corp
  • Cellatoz Therapeutics Inc
  • Cells for Cells SA
  • Denteric Pty Ltd
  • Geistlich Pharma AG
  • GEXVal Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H2 2020, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews the key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 5, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Beijing SH Bio-Tech Corp
  • Cellatoz Therapeutics Inc
  • Cells for Cells SA
  • Denteric Pty Ltd
  • Geistlich Pharma AG
  • GEXVal Inc

Introduction
Report Coverage
  • Periodontitis - Overview
  • Periodontitis - Therapeutics Development

Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Periodontitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Periodontitis - Companies Involved in Therapeutics Development
  • Amyndas Pharmaceuticals LLC
  • Beijing SH Bio-Tech Corp
  • Cellatoz Therapeutics Inc
  • Cells for Cells SA
  • Denteric Pty Ltd
  • Geistlich Pharma AG
  • GEXVal Inc
  • Guangzhou Saliai Stemcell Science and Technology Co Ltd
  • KIMS Pharmaceutical Co Ltd
  • MetiMedi Pharmaceuticals Co Ltd
  • Noveome Biotherapeutics Inc
  • PerioTrap Pharmaceuticals GmbH
  • TGV Laboratories Inc

Periodontitis - Drug Profiles
  • AMY-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLZ-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Antagonize C5aR for Periodontitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Periodontitis - Dormant Projects
  • Periodontitis - Discontinued Products
  • Periodontitis - Product Development Milestones

Featured News & Press Releases
  • Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
  • Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
  • Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
  • Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis
  • May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development for Periodontitis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020
  • Periodontitis - Pipeline by Beijing SH Bio-Tech Corp, H2 2020
  • Periodontitis - Pipeline by Cellatoz Therapeutics Inc, H2 2020
  • Periodontitis - Pipeline by Cells for Cells SA, H2 2020
  • Periodontitis - Pipeline by Denteric Pty Ltd, H2 2020
  • Periodontitis - Pipeline by Geistlich Pharma AG, H2 2020
  • Periodontitis - Pipeline by GEXVal Inc, H2 2020
  • Periodontitis - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H2 2020
  • Periodontitis - Pipeline by KIMS Pharmaceutical Co Ltd, H2 2020
  • Periodontitis - Pipeline by MetiMedi Pharmaceuticals Co Ltd, H2 2020
  • Periodontitis - Pipeline by Noveome Biotherapeutics Inc, H2 2020
  • Periodontitis - Pipeline by PerioTrap Pharmaceuticals GmbH, H2 2020
  • Periodontitis - Pipeline by TGV Laboratories Inc, H2 2020
  • Periodontitis - Dormant Projects, H2 2020
  • Periodontitis - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Periodontitis - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Periodontitis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Amyndas Pharmaceuticals LLC
  • Beijing SH Bio-Tech Corp
  • Cellatoz Therapeutics Inc
  • Cells for Cells SA
  • Denteric Pty Ltd
  • Geistlich Pharma AG
  • GEXVal Inc
  • Guangzhou Saliai Stemcell Science and Technology Co Ltd
  • KIMS Pharmaceutical Co Ltd
  • MetiMedi Pharmaceuticals Co Ltd
  • Noveome Biotherapeutics Inc
  • PerioTrap Pharmaceuticals GmbH
  • TGV Laboratories Inc
Note: Product cover images may vary from those shown